author-photo

K. Sarantseva

Academy of Medical Sciences, United Kingdom

5

Papers

2

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim results of observational prospective study.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Observational study of the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
1317PMulticenter observational study of the efficacy and safety of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)